Importantly, these tumours behave similarly as compared to their mutated peers; for instance, BRAF-like tumours are equally associated with poor prognosis, but might be sensitive to microtubule-targeting chemotherapeutics56,58 and EGFR-activated cancers do not respond to cetuximab, but might be sensitive to drugs targeting downstream effectors in this pathway57. The gene discussed is EGFR; the disease is neoplasm.